“Dry Eye Disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.
The Dry Eye Disease Pipeline report provides a comprehensive evaluation of pipeline products, spanning from pre-clinical development to market availability, with a focus on commercial and clinical aspects. It includes a detailed overview of each drug, encompassing its mechanism of action, clinical studies, potential NDA approvals, and various product development activities. These activities involve technology, collaborations, mergers, acquisitions, funding, designations, and other pertinent details related to the products in the pipeline.
Some of the key takeaways from the Dry Eye Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years.
Dry Eye Disease companies working in the treatment market are Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others, are developing therapies for the Dry Eye Disease treatment
Emerging Dry Eye Disease therapies in the different phases of clinical trials are- Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.
In January 2025, Stuart Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing innovative treatments for ophthalmic diseases, has announced the completion of the last patient’s last visit in its Phase III clinical trial evaluating ST-100 (vezocolmitide) as a potential therapy for Dry Eye Disease.
In August 2024, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX), a biotechnology company focused on developing innovative treatments for immune-mediated and metabolic diseases, has announced that its Phase 3 clinical trial for 0.25% reproxalap ophthalmic solution, an investigational drug for dry eye disease, has met its primary endpoint. The randomized, double-masked, vehicle-controlled dry eye chamber trial demonstrated that reproxalap showed statistically significant superiority over the vehicle in reducing ocular discomfort (P=0.004), a symptom recognized by the U.S. Food and Drug Administration (FDA) for dry eye disease treatment.
In August 2024, Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company specializing in melanocortin receptor-modulating therapies, has received FDA confirmation regarding the acceptability of protocols and endpoints for the Phase 3 pivotal trials of PL9643 for dry eye disease (DED). The ongoing Phase 3 clinical program includes two studies, MELODY-2 and MELODY-3, both of which will evaluate sign and symptom endpoints to assess the treatment’s efficacy.
Dry Eye Disease Overview
A lack of tear film homeostasis is the cause of dry eye disease (DED), also referred to as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca. DED is a multifactorial illness of the ocular surface.
Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dry-eye-disease-pipeline-insight
Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:
Qi 401: Quorum Innovations
SER-114: Serentrix
iVIEW 1001: IVIEW Therapeutics
TJO-083: Taejoon Pharmaceutical
SY-201: Seinda Pharmaceutical
INV-102: Invirsa
GLH8NDE: GL Pharm Tech Corporation
SHJ 002: Dreamhawk Vision Biotech, Inc
A197: Aramis Biosciences
K-161: Kowa Company
AR-15512: Alcon
HL036: HanAll Biopharma
SI-614: Seikagaku Corporation
NOV03: Novaliq GmbH
CyclASol: Novaliq GmbH
Dry Eye Disease Route of Administration
Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Dry Eye Disease Molecule Type
Dry Eye Disease Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Dry Eye Disease Pipeline Therapeutics Assessment
Dry Eye Disease Assessment by Product Type
Dry Eye Disease By Stage and Product Type
Dry Eye Disease Assessment by Route of Administration
Dry Eye Disease By Stage and Route of Administration
Dry Eye Disease Assessment by Molecule Type
Dry Eye Disease by Stage and Molecule Type
DelveInsight’s Dry Eye Disease Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the emerging Dry Eye Disease therapies
Some of the key companies in the Dry Eye Disease Therapeutics Market include:
Key companies developing therapies for Dry Eye Disease are – AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson & Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, VISUfarma, and others.
Dry Eye Disease Pipeline Analysis:
The Dry Eye Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dry Eye Disease drugs and therapies
Dry Eye Disease Pipeline Market Drivers
Rise in geriatric population, increasing Exposure to computer screens, increased R&D Activities, adoption of new Technologies are some of the important factors that are fueling the Dry Eye Disease Market.
Dry Eye Disease Pipeline Market Barriers
However, lack of awareness about dry eye disease in low income countries, complexity of the disease, challenges associated with the Ocular drug delivery and other factors are creating obstacles in the Dry Eye Disease Market growth.
Scope of Dry Eye Disease Pipeline Drug Insight
Coverage: Global
Key Dry Eye Disease Companies: Quorum Innovations, Serentrix, IVIEW Therapeutics, Taejoon Pharmaceutical, Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc, Aramis Biosciences, Kowa Company, Alcon, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others
Key Dry Eye Disease Therapies: Qi 401, SER-114, iVIEW 1001, TJO-083, SY-201, INV-102, GLH8NDE, SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
Request for Sample PDF Report for Dry Eye Disease Pipeline Assessment and clinical trials
Table of Contents
1. Dry Eye Disease Report Introduction
2. Dry Eye Disease Executive Summary
3. Dry Eye Disease Overview
4. Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment
5. Dry Eye Disease Pipeline Therapeutics
6. Dry Eye Disease Late Stage Products (Phase II/III)
7. Dry Eye Disease Mid Stage Products (Phase II)
8. Dry Eye Disease Early Stage Products (Phase I)
9. Dry Eye Disease Preclinical Stage Products
10. Dry Eye Disease Therapeutics Assessment
11. Dry Eye Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Dry Eye Disease Key Companies
14. Dry Eye Disease Key Products
15. Dry Eye Disease Unmet Needs
16 . Dry Eye Disease Market Drivers and Barriers
17. Dry Eye Disease Future Perspectives and Conclusion
18. Dry Eye Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
